Telford Bryony J, Yahyanejad Sanaz, de Gunst Thijs, den Boer Harm C, Vos Rogier M, Stegink Marieke, van den Bosch Marion T J, Alemdehy Mir Farshid, van Pinxteren Laurens A H, Schaapveld Roel Q J, Janicot Michel
InteRNA Technologies BV, Utrecht, The Netherlands.
Oncotarget. 2021 Mar 2;12(5):422-439. doi: 10.18632/oncotarget.27894.
Compelling evidence demonstrates that miR-193a-3p is a tumor suppressor microRNA in many cancer types, and its reduced expression is linked to cancer initiation and progression, metastasis, and therapy resistance. However, its mechanism of action is not consistently described between studies, and often contradicts the pleiotropic role of a microRNA in manipulating several different mRNA targets. We therefore comprehensively investigated miRNA-193a-3p's mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic. Interestingly, the exact mechanism through which 1B3 reduced cell proliferation varied between cell lines. 1B3 efficiently reduced target gene expression, leading to reduced cell proliferation/survival, cell cycle arrest, induction of apoptosis, increased cell senescence, DNA damage, and inhibition of migration. SiRNA silencing of 1B3 target mRNAs further highlighted the advantage of the pleiotropic mechanism of 1B3 action, as repression of individual targets did not achieve the same robust effect on cell proliferation in all cell lines. Importantly, a novel lipid nanoparticle-based formulation of 1B3, INT-1B3, demonstrated marked anti-tumor activity as a single agent following systemic administration in tumor-bearing mice. Together, these data strongly support the development of 1B3 as a novel therapeutic agent for treatment of human cancer.
有力证据表明,miR-193a-3p在多种癌症类型中是一种肿瘤抑制性微小RNA,其表达降低与癌症的发生、发展、转移及治疗耐药性相关。然而,不同研究对其作用机制的描述并不一致,且常常与微小RNA在调控多个不同mRNA靶点时的多效性作用相矛盾。因此,我们使用合成微小RNA模拟物1B3,在一组具有多种遗传背景的人类癌细胞系中全面研究了miRNA-193a-3p的作用模式。有趣的是,1B3降低细胞增殖的确切机制在不同细胞系中有所不同。1B3有效降低了靶基因表达,导致细胞增殖/存活减少、细胞周期停滞、凋亡诱导、细胞衰老增加、DNA损伤以及迁移抑制。对1B3靶mRNA进行SiRNA沉默进一步凸显了1B3作用的多效性机制的优势,因为抑制单个靶点在所有细胞系中对细胞增殖并未产生同样强大的作用。重要的是,一种基于脂质纳米颗粒的新型1B3制剂INT-1B3,在荷瘤小鼠全身给药后作为单一药物显示出显著的抗肿瘤活性。总之,这些数据有力支持将1B3开发为治疗人类癌症的新型治疗药物。